ClinicalTrials.gg
RecruitingNCT05904119LEGATOUpdated Jun 8, 2026

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

A Phase 3 interventional study of Lomustine and Reirradiation in First Progression of Glioblastoma, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Recruiting at 45 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
411
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC — 1 open to participants now, 1 under way, 1 of them phase 3. Glioblastoma · European Organisation for Research and Treatment of Cancer - EORTC.

Planned enrollment
4th of 18
411 · median 55
Started
2024
the only one that year
Phase 3
5 of 20
1 open now
Registered
20th of 20
by date

Among the 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 3, and was the 20th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

1 of the 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC is open now, in 11 countries.

By country, each count listing its studies:

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC, or all of them as a file.
02

Study summary

Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses. Treatment options include repeated surgery (if feasible), systemic therapy (bevacizumab, lomustine, temozolomide re-challenge), reirradiation and best supportive care. Currently, the superiority of combined chemoradiation versus chemotherapy alone remains unproven. Given that lomustine is the standard chemotherapeutic agent for the treatment of recurrent glioblastoma in Europe and the unclear efficacy of reirradiation, we want to explore whether combining lomustine and reirradiation may be a better treatment than lomustine alone. The results of the prospective randomized trial proposed here should demonstrate a significant improvement in overall survival when lomustine is combined with reirradiation in patients with recurrent glioblastoma compared to lomustine alone without adversely affecting quality of survival. The trial will be stopped based on overall survival in a preplanned futility and efficacy interim analysis.

03

Conditions studied

  • First Progression of Glioblastoma

Browse trials for

Keywords

  • First progression
  • Glioblastoma
  • Phase III
  • Lomustine
  • Reirradiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before patient's enrolment, written must be given according to ICH/GCP, and national/local regulations.
  • Patients with first progression or recurrent glioblastoma after standard chemoradiotherapy (any treatment other than use of nitroureas) having occurred at least 6 months after the end of prior radiotherapy
  • according to RANO criteria with a maximum tumour diameter of 5 cm (local investigator assessment)
  • In case of surgery for recurrence: fully recovered from surgery, confirmation of recurrence by histology, and patient fit for treatment as per local investigator assessment.
  • proven diagnosis of glioblastoma, IDH wildtype per WHO 2021 classification and local assessment of tissue from diagnosis or recurrence
  • Initial treatment of newly diagnosed glioblastoma by maximal safe resection and postsurgical concurrent conventionally fractionated or abbreviated (minimum 15 fractions) chemoradiotherapy with or without maintenance chemotherapy with temozolomide (patient must have received at least one dose)
  • Stable or decreasing dose of for 7 days prior to enrolment
  • Age ≥ 18 years
  • of 0-2
  • Women of (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
  • Patients of childbearing / must agree to use adequate measures during the study treatment period and for at least 6 months after the last dose of study treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.
  • Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
  • Non-sterile males must use contraception during treatment and for 6 months after the last dose.
  • Non-sterile males must avoid sperm donation for the duration of the study and for at least 6 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any prior anticancer treatment for recurrent glioblastoma (except surgery)
  • Significant reduction in and/or leukocyte counts as well as severe renal impairment according to investigator's opinion
  • History or present acute leukaemia or any myeloid disease
  • Known to the active components or of lomustine
  • Known coeliac disease or wheat allergy
  • in the 3 months prior to lomustine initiation
  • Any serious or uncontrolled medical condition (e.g., infections, chronic alcoholism, drug addiction) or abnormality, in the judgment of the investigator that prohibits obtaining , safe participation and study completion
  • Known to imaging tracer or any product of contrast media and Magnetic Resonance Imaging (MRI) contraindications
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
411 participants (estimated)

Study arms

  • Active comparator
    Control group

    Lomustine alone

    Drug: Lomustine

  • Experimental
    Experimental group

    Lomustine plus reirradiation

    Drug: Lomustine · Radiation: Reirradiation

Interventions

  • Oral administration of Lomustine

  • RadiationReirradiation

    Given at least 6 months after the end of prior radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the number of days from date of enrolment to the date of death due to any cause

    Time frame: From the date of enrolment up to the date of death, assessed up to 40 months after first patient is enrolled

Secondary outcomes

  1. Progression Free Survival (PFS)

    Events are progressions based on Response Assessment in Neuro Oncology (RANO) criteria as determined by the local investigator .

    Time frame: From the date of enrolment up to the date of first objective progression or the date of death whichever occur first, assessed up to 40 months after first patient is enrolled

  2. Health-related Quality of Life (HRQoL)

    HRQoL will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3.

    Time frame: From the date of enrolment until disease progression, assessed up to 40 months after first patient is enrolled

  3. Toxicity profile of lomustine plus reirradiation

    Safety according to the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.0 for toxicity and Serious Adverse Event reporting.

    Time frame: From the date of enrolment until end of study treatment 30 (± 7 days) after last dose, assessed up to 40 months after first patient is enrolled

  4. Neurocognitive functioning of lomustine pus reirradiation

    Neurocognitive functioning assessed by Mini Mental State Examination (MMSE)

    Time frame: From the date of enrolment until end of study treatment 30 (± 7 days) after last dose, assessed up to 40 months after first patient is enrolled

  5. To transform self-reported quality of life data from the QLQ-C30 into health utility values, ready to be used in subsequent health economic analyses.

    A deterioration event is defined as ≥\>10-point worsening from baseline in the GHQ without further improvement (i.e., no subsequent ≥\>10 point improvement) or death due to any cause.

    Time frame: From the date of enrolment until disease progression, assessed up to 40 months after first patient is enrolled

  6. Objective response (ORR)

    Time frame: From the date of enrolment up to the date of first objective progression or the date of death whichever occur first, assessed up to 40 months after first patient is enrolled

  7. Complete response (CRR)

    Time frame: From the date of enrolment up to the date of first objective progression or the date of death whichever occur first, assessed up to 40 months after first patient is enrolled

Other outcomes

  1. To assess health-related quality of life over time based on the results of 3 different scales (QLQ-C30, QLQ-BN20 and the item list (IL46)).

    Changes in HRQoL from baseline in the GHQ/QoL, fatigue, nausea/vomiting, physical, role and social functioning scale scores assessed over time will be evaluated descriptively. Descriptive summaries such as median, range (minimum, maximum), IQR, mean and standard deviation will be provided for all the other scales from the QLQ-C30, QLQ-BN20 and the item list (IL46). For functional and global HRQoL scales, higher scores represent a better level of functioning and are converted to a 0 to 100 scale. For symptom-oriented scales, a higher score represents more severe symptoms.

    Time frame: From the date of enrolment until disease progression, assessed up to 40 months after first patient is enrolled

07

Study locations

42 of 45 sites recruiting
  • A.O Landeskrankenhaus - Innsbruck Universitaetsklinik
    Innsbruck, 6020, Austria
    Recruiting
  • Kepler University Hospital - Neuromed campus
    Linz, 4020, Austria
    Recruiting
  • Universitaetsklinikum Wien - AKH unikliniken
    Vienna, Austria
    Recruiting
  • AZORG
    Aalst, 9300, Belgium
    Recruiting
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
    Recruiting
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Recruiting
  • Grand Hopital de Charleroi - Site Les Viviers
    Gilly, 6060, Belgium
    Recruiting
  • U.Z. Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
    Recruiting
  • Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus (previous GZA)
    Wilrijk, 2610, Belgium
    Recruiting
    • Katrien Erven · Principal investigator
  • Masaryk Memorial Cancer Institute
    Brno, Czechia
    Recruiting
  • Aarhus University Hospitals - Region Midtjylland - Aarhus University Hospital-Skejby
    Aarhus, 8200, Denmark
    Recruiting
  • CHU d'Amiens - CHU Amiens Picardie - Site Sud
    Amiens, 80054, France
    Recruiting
  • CLCC - Jean Perrin
    Clermont-Ferrand, 63000, France
    Recruiting
  • CHRU de Lille
    Lille, 59037, France
    Recruiting
  • CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer
    Lyon, France
    Recruiting
  • Institut du Cancer de Montpellier
    Montpellier, France
    Recruiting
  • CHU de Nice - Hôpital Pasteur
    Nice, 06000, France
    Recruiting
  • Assistance Publique Hopitaux Paris- APHP - APHP Sorbonne Univ - Hopital la Pitie-Salpetriere (233)
    Paris, 75013, France
    Recruiting
  • Assistance Publique Hopitaux Paris- APHP - APHP Nord - Univ De Paris Cite - Hop. Saint Louis
    Paris, France
    Recruiting
  • Institut de Cancerologie de l´Ouest (ICO) - Saint Herblain
    Saint-Herblain, 44805, France
    Recruiting
  • Institut Public De Cancerologie Strauss Europe-Strauss Institute
    Strasbourg, 67200, France
    Recruiting
    • Roland Schott · Principal investigator
  • Univ. Knappschaft Krankenhaus Bochum
    Bochum, 44892, Germany
    Recruiting
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
    Recruiting
  • Universitaetsklinikum Erlangen-Schwabachanlage
    Erlangen, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum - Essen
    Essen, 45147, Germany
    Recruiting
    • Sied Kebir · Principal investigator
  • Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital
    Heidelberg, 69120, Germany
    Recruiting
  • Universitätsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie
    Leipzig, 04103, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern
    Munich, 81377, Germany
    Recruiting
  • Universitaetskliniken Regensburg - Universitaetsklinikum Regensburg
    Regensburg, 93053, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Tuebingen- Crona Kliniken
    Tübingen, 72076, Germany
    Recruiting
  • IRCCS-Ospedale Bellaria-Bologna
    Bologna, 40139, Italy
    Recruiting
  • ULSS 9 Scaligera Veneto - Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital
    Legnago, 37045, Italy
    Recruiting
  • Istituto Clinico Humanitas
    Milan, 20089, Italy
    Recruiting
  • IRCCS - Istituto Oncologico Veneto
    Padova, 35128, Italy
    Recruiting
  • Azienda ospedaliero Univ Policlinico Umberto I
    Roma, 00161, Italy
    Recruiting
  • Leiden University Medical Centre
    Leiden, Netherlands
    Recruiting
  • Erasmus MC
    Rotterdam, Netherlands
    Recruiting
  • ETZ Tilburg - ETZ - St. Elisabethziekenhuis
    Tilburg, 5022, Netherlands
    Recruiting
  • Oslo University Hospital - Radiumhospitalet
    Oslo, NO 0379, Norway
    Recruiting
  • St Olavs University Hospital - St. Olavs Hospital, Trondheim University Hospital
    Trondheim, NO 7030, Norway
    Recruiting
  • Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) (381)
    Badalona, 08916, Spain
    Recruiting
  • ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
    L'Hospitalet de Llobregat, 08908, Spain
    Recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
  • Oncology Institute of Southern Switzerland (IOSI) - Ospedale San Giovanni
    Bellinzona, 6500, Switzerland
    Recruiting
  • UniversitaetsSpital Zurich - Neurology Clinic
    Zurich, 8091, Switzerland
    Recruiting
    • Emilie Le Rhun · Principal investigator
08

References and documents

Publications

  • Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, Koekkoek JA, Monti AF, Csanadi M, Pitter JG, Bulbek H, Fournier B, Quoilin C, Gorlia T, Weller M, Minniti G; European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. Trials. 2024 Jun 7;25(1):366. doi: 10.1186/s13063-024-08213-7. PubMed 38849943 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2027, 42 months after the start.

Of 44 phase 3 interventional studies under Glioblastoma, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 87. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jun 15, 2023
StartActual
Mar 15, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Feb 2028
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05904119
Collaborators
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Mar 15, 2024
Primary completion
Sep 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 8, 2026

Study contacts

EORTC
Contact
eortc@eortc.org
+3227741611
Matthias Preusser, Prof.
principal investigator · EORTC Study Coordinator
Giuseppe Minniti, Dr.
principal investigator · EORTC Study Coordinator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion